Summary The standard management of primary gastric lymphoma (PGL) (stage 11) has not been established despite the use of various treatment modalities. The present prospective trial of combined surgery and chemotherapy for the treatment of PGL (stage 11) included 25 consecutive patients treated between July 1978 and December 1993. Twenty-one patients were treated with total gastrectomy and four with partial gastrectomy; this was followed by post-operative chemotherapy with m-VEPA (vincristine, cyclophosphamide, prednisolone and doxorubicin), followed by consolidation chemotherapy with VEMP (vindesine, cyclophosphamide, methotrexate and prednisolone) or VQEP (vindesine, carbazilquinone, cyclophosphamide and prednisolone). Twenty-one of the 25 patients who completed post-operative chemotherapy were free of relapse 26-203 (median 94) months after the gastrectomy. Of the four patients who did not complete the projected chemotherapy, two relapsed and died of lymphoma. Another patient with recurrent lymphoma died in an accident, and the fourth patient was in remission at 54 months after surgery. The post-operative overall and disease-free survival rates at 10 years for the 25 evaluable patients were 81.6% and 92.0% respectively. Major surgical complications and treatment-related death after chemotherapy were not observed. PGL (stage 11) appears to be curable when treated with gastrectomy and adjuvant chemotherapy.
The stomach is the most common site of extranodal lymphomas, accounting for about 24% of cases (Freeman et al, 1972) . Although localized (stage I and II) primary gastric lymphoma (PGL) has been treated by various modalities, including surgery (Shiu et al, 1982) , chemotherapy (Maor et al, 1984 : Salles et al, 1991 , surgery plus radiotherapy (Shiu et al, 1982; Gospodarowicz et al, 1983; Taal et al, 1993) , surgery plus chemotherapy (Paulson et al, 1983; Sheridan et il, 1985; Shepherd et al, 1988; Bellesi et al, 1989; Pasini et al, 1994) and radiotherapy plus chemotherapy (Burgers et al, 1988; Dragosics et al, 1985 , Maor et al, 1990 Tondini et al, 1993) , the best management for this disease is still unclear.
During the last two decades, many combination chemotherapy regimens including doxorubicin (McKelvey et al, 1976; Rodriguez et al, 1977; Skarin et al, 1977) were developed for patients with aggressive non-Hodgkin's lymphoma (NHL), and the treatment of advanced-stage NHL patients has been one of the major successes of cancer therapy.
A combination chemotherapy known as VEM(N)P [vincrinstine, cyclophosphamide (Endoxan), 6-mercaptopurine or procarbazine, and prednisolone (Sakai, 1976) ] was regarded in Japan around 1975 as a standard regimen for patients with advanced malignant lymphoma. At that time, we treated two patients with resection; they survived without relapse for over 9 years (Takenaka et al, 1981) .
The Japanese Lymphoma Study Group began a prospective study of advanced NHL patients treated with VEPA chemotherapy (vincrinstine, cyclophosphamide, prednisolone and doxorubicin) (Lymphoma Study Group, 1979; Shimoyama et al, 1988 Shimoyama et al, ) in 1978 In that trial, consolidation chemotherapy using various regimens, including VEMP (vindesine, cyclophosphamide, methotrexate and prednisolone) and VQEP (vindesine, carbazilquinone, cyclophosphamide and prednisolone), was planned to continue monthly for at least 2 years. In our pilot study of six advanced and/or nonresectable PGL patients treated with a VEPA-like regimen, a complete response was observed in 50% and partial response in 17% of the patients (Takenaka et al, 1982) .
To avoid the problems associated with the interpretation of the wide variation in results obtained using different treatment approaches in retrospective studies, we began a prospective trial of combined surgery and chemotherapy for the treatment of PGL (stage II) patients in 1978. The results are presented here.
PATIENTS AND METHODS Patients
Sixty-seven patients were diagnosed as having PGL [defined according to the modified criteria of Dawson (1961) ] and 61 of these patients (91%) underwent gastrectomy at the NCC Hospital between July 1978 and December 1993. Twenty-nine patients were diagnosed as having stage II disease according to the Ann Arbor classification (Carbone et al, 1971) . Of these patients, 25 agreed to enter into the trial. Project, 1982) .
In addition, surgical specimens were re-evaluated if histological features indicating an origin from mucosa-associated lymphoid tissue (MALT) (Isaacson et al, 1983) were present and classified into the following three groups: MALT lymphoma with or without areas of large-cell cytology (low-grade MALT); diffuse large-cell lymphoma with areas showing MALT features (high-grade MALT); and diffuse large-cell lymphoma without MALT features (non-MALT).
Statistics
Survival was calculated from the date of surgery to the last followup or to the date of death. The last follow-up date was August 1996. Survival curves were plotted using the Kaplan-Meier method (Kaplan and Meier, 1958) .
RESULTS

Surgery and clinicopathological findings
Radical tumour resection with curative intent was performed in 61 consecutive patients with PGL. Of the 29 patients diagnosed as having stage II disease, three patients elected to be treated by second-generation chemotherapy as post-operative chemotherapy and another patient refused adjuvant treatment.
The remaining 25 PGL (stage II) patients were enrolled in the study (Table 2) . Fourteen patients were women and 11 were men. Their ages at presentation ranged from 36 to 82 (median 56) years. In 4 of the 25 patients, partial gastrectomy was performed; total gastrectomy was performed in the other 21.
The size of the primary tumour varied from 3.4 to 20.0 (median 10.5) cm in the maximum diameter. Twenty patients were classified as having diffuse large cell lymphoma, three as mixed small and large cell, one as diffuse small cleaved cell and one as follicular predominantly large cell lymphoma. All patients were classified as having intermediate-grade lymphoma (WF-system).
Three of the 22 re-evaluated patients were classified as having low-grade MALT lymphoma and 13 patients as having high-grade MALT lymphoma. The remaining six patients were classified as having non-MALT lymphoma.
The depth of tumour infiltration into the gastric wall was the submucosa in seven patients, muscularis propria in five, subserosa in five and serosa without the involvement of adjacent organs in eight.
British Journal of Cancer (1997) 76(11) consolidation chemotherapy in 8 of the 25 patients, no thrombocytopenia (< 10 x 104 l-') was observed.
DISCUSSION
Of the various modalities used to treat PGL, surgical resection is the most commonly used initial treatment. The role of surgery in the management of PGL is to ensure an accurate histopathological diagnosis, reduce tumour bulk, relieve symptoms and prevent bleeding and perforation. Although the actual frequency of chemotherapy-related bleeding or perforation is not clear, the frequency of these complications in unresected patients with gastrointestinal lymphoma reported previously varies from 0% to 20% (Brooks et al, 1983; Gobbi et al, 1984; Rosenfelt et al, 1980) . Another important aspect of surgery is tumour staging, and many authors have reported that this is the most important prognostic factor affecting survival (Lim et al, 1977; Shiu et al, 1982; Brooks et al, 1983; Dragosics et al, 1985; Hockey et al, 1987) Any additional treatment is based on the pathological stage, and surgical exploration with gastrectomy is the only means of achieving this.
Favourable results for stage I and II PGL using surgical resection followed by chemotherapy have been reported by several authors (Paulson et al, 1983; Sheridan et al, 1985; Shepherd et al, 1988; Bellesi et al, 1989; Pasini et al, 1994) , but these reports failed to discriminate between stage I and stage II disease. In the present study, we focused on stage II PGL because the results obtained from a previous study (Takenaka et al, 1981) suggested that: (a) stage I PGL is cured by gastrectomy alone; and (b) stage II PGL relapses occasionally without adjuvant chemotherapy.
In our hospital (during the same period as our stage II study), 27 consecutive stage I PGL patients were treated by total gastrectomy alone. After 14-205 (median 99) months of follow-up, none has shown any sign of relapse (unpublished data). These results concur with the hypothesis that post-operative chemotherapy is not necessary for stage I PGL patients (Takenaka et al, 1981; Paulson et al, 1983) .
Discrimination between stage II, and stage II2 using Musshoff's staging system (Musshoff, 1977) was difficult in this study, because established staging procedures were not used. However, the results of the present study show that stage II PGL is curable with well-planned chemotherapy after surgical resection. Considering that a definite prognostic difference exists between stage II, and stage "2 patients (Dragosics et al, 1984) , further study is necessary to develop the best treatment modalities for stage 11, and stage 112 determined by established staging procedures.
The present adjuvant chemotherapy regimen consisting of post-operative chemotherapy with m-VEPA and consolidation chemotherapy with VQEP or VEMP requires about 2 years for completion. It is important to determine whether consolidation chemotherapy is necessary for the prevention of recurrence. No relapses were observed in the present study between 20 and 49 months among the five patients who refused consolidation chemotherapy. Adjuvant chemotherapy regimens for PGL stage II patients should be studied further and selected with consideration of both treatment duration and effectiveness. Considering a previous report on aggressive lymphoma (Fisher et al, 1993) , we suggest that the standard CHOP regimen is a valid form of chemotherapy. We began an adjuvant chemotherapy study of PGL stage II patients using a CHOP regimen in November 1994. Severe toxicities and relapses have not been observed to date.
To preserve the stomach, patients with localized PGL have been treated with chemotherapy, radiotherapy and chemotherapy plus radiotherapy. Burgers et al (1988) reported a 4-year disease-free survival rate of 83% in 24 patients with stage I PGL treated with whole abdominal radiotherapy with a gastric bed boost. Maor et al (1990) reported a 5-year disease-free survival rate of 62% in 34 patients with stage I and II PGL treated with combination chemotherapy and involved-field radiotherapy. These results are not superior to our survival rate and disease-free survival rate obtained by surgery plus adjuvant chemotherapy. Although combination chemotherapy as an initial treatment has been shown to be useful in PGLs (Maor et al, 1984; Salles et al, 1991) , data are not available concerning the treatment of localized PGL with chemotherapy alone.
Helicobacter pylori is present in 92% of gastric low-grade MALT lymphomas (Wotherspoon et al, 1991) . After the eradication of H. pylori with antibiotics, five out of six low-grade gastric B-cell MALT lymphomas showed no evidence of lymphoma (Wotherspoon et al, 1993) . However, the patients enrolled in the present study were not examined for H. pylori infection; that is a future task.
In addition, most low-grade MALT lymphomas are at stage IE; a minority are at stage II,, according to Isaacson and Norton (1994) . Only three (14%) of our stage II patients had low-grade MALT lymphoma. Interestingly, of our 22 stage I patients re-evaluated histologically, 16 cases were classified as low-grade MALT lymphoma, two as high-grade and four as non-MALT lymphoma (unpublished data 
